Our IP Commercialisation Team have extensive experience of partnering with companies to license innovative technologies developed at the University of Liverpool and are skilled in taking these new products and services to market.
The University places importance on supporting academics and researchers through the process of commercialising their research. This is evident through the University’s Enterprise Investment Fund (EIF) scheme. Funding is available for staff to de-risk technologies developed at the University, for commercialisation with industry, typically leading to a licence deal or spin-out.
A list of technologies currently available for licensing can be found below:
A technology for the detection of Streptococcus pneumoniae, Streptococcus pyogenes and Staphylococcus aureus toxins.
Biomarkers to identify patient populations at most risk of pancreatic cancer.
Molecules that can interact with different complement components, to selectively inhibit specific pathways of complement activation.
A device to obtain high quality images of the cornea and retina to facilitate diagnosis and management of corneal and retinal diseases.
A new approach for ocular drug delivery which can alter drug release rates into aqueous environments, including the eye.
A prototype vaccine that can greatly reduce transmission of parasitic nematodes for the prevention and/or treatment of infections in dogs.
A simple, low-cost device that has been developed to make bimanual compression of the uterus simple and non-invasive.
A chemistry strategy for HPD synthesis that utilises low genera on dendron-based initiators and chain-growth branching polymerisation.
A molecularly engineered protein-based PSC culture substrate that can be easily and cheaply produced.
A Single Nuclear Polymorphism (SNP) in a gene that increases the risk of developing adrenal suppression using inhaled corticosteroids (ICS).
Manipulating structural chemistry in thermoelectric materials offers enhanced efficiency in energy production.
A new pump design which requires very low levels of maintenance, decreasing the cost of ownership and losses caused by pump failure.
Cage molecule solids have been designed and synthesised that efficiently capture low-concentration pollutants.
